SCHEMBL19385076

SCHEMBL19385076

N#CN1CCC(c2cc(-c3ccc(S(=O)(=O)N4CCOCC4)cc3)n[nH]2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19385145 0.90 USP30 (1.00) USP30
SCHEMBL22555684 0.80 USP30 (0.67) USP30
SCHEMBL19385251 0.78 USP30 (1.00) USP30
SCHEMBL19385412 0.76 USP30 (1.00) USP30
SCHEMBL19385204 0.75 USP30 (0.79) USP30
SCHEMBL19385218 0.73 USP30 (1.00) USP30
SCHEMBL19385369 0.73 USP30 (1.00) USP30
SCHEMBL19400758 0.72 USP30 (1.00) USP30
SCHEMBL29562372 0.71 USP30 (1.00) USP30
SCHEMBL19385001 0.71 USP30 (1.00) USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352339-B2 1-cyano-pyrrolidine derivatives as DUB inhibitors MISSION THERAPEUTICS LIMITED (GB) 2022-06-07 — — US claimed
EP-3433246-B1 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS MISSION THERAPEUTICS LTD (GB) 2022-05-04 — — EP claimed
CN-108884068-B 1-cyano-pyrrolidine derivatives as DUB inhibitors 特殊治疗有限公司 2021-02-26 — — CN claimed
US-20200331888-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-10-22 — — US claimed
EP-3433246-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS Mission Therapeutics Limited (GB) 2019-01-30 — — EP claimed
WO-2017163078-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2017-09-28 — — WO claimed
US-11945797-B2 1-cyano-pyrrolidine derivatives as dub inhibitors MISSION THERAPEUTICS LIMITED (GB) 2024-04-02 — — US disclosed
US-20220177451-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2022-06-09 — — US disclosed
US-11352339-B2 1-cyano-pyrrolidine derivatives as DUB inhibitors MISSION THERAPEUTICS LIMITED (GB) 2022-06-07 — — US disclosed
EP-3433246-B1 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS MISSION THERAPEUTICS LTD (GB) 2022-05-04 — — EP disclosed
CN-108884068-B 1-cyano-pyrrolidine derivatives as DUB inhibitors 特殊治疗有限公司 2021-02-26 — — CN disclosed
US-20200331888-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-10-22 — — US disclosed
EP-3433246-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS Mission Therapeutics Limited (GB) 2019-01-30 — — EP disclosed
WO-2017163078-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2017-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352339-B2 1-cyano-pyrrolidine derivatives as DUB inhibitors USP30, USP28, USP1 USP30 1/4885
US-20220177451-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS USP30, USP28, USP1 USP30 1/4885
US-11945797-B2 1-cyano-pyrrolidine derivatives as dub inhibitors USP30, USP28, USP1 USP30 1/4885
US-20200331888-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS USP30, USP28, USP1 USP30 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback